GSK Plc ADR Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $43.9B+11.8% YoYTTM through 31 Dec 2025
Net Income $7.7B+138.4% YoYTTM through 31 Dec 2025
Free Cash Flow $8.6BTTM through 31 Dec 2025
Margins
| Current | |
|---|---|
| EBITDA Margin | 31.4% |
| Operating Margin | 24.3% |
| Net Margin | 17.5% |
Returns
35.8%ROE
9.3%ROA
Balance Sheet Health
Current Ratio0.82x
Cash & Equivalents$3.4B
Quality Metrics
Piotroski F-Score7 / 9
FCF Margin19.6%
Rule of 4023.7
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $32.7B
Diluted EPSFY2025: $1.39
Dividend
$0.95Per share, FY20261.87%Yield-15.6%5-yr growth
Capital Allocation
Capex Intensity3.1%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Specialty Medicines | $13.5B | +17.0% | View detailsDriven by long-acting HIV medicines (Cabenuva) and oncology launches. |
| Vaccines | $9.2B | +2.0% | View detailsCentral focus for the group with ongoing geographic expansion. |
| General Medicines | $10B | -1.0% | View detailsRemains under pressure due to pricing pressures and generic competition. |
Financials converted at 0.7425 from GBP.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.